Get started
Author

Natalie Maimon

Pretreatment Neutrophil-to-Lymphocyte Ratio in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Ketoconazole: Association with Outcome and Predictive Nomogram
2012 · Daniel Keizman, Maya Gottfried, et al. · The Oncologist · 90
PDF
Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
2013 · Daniel Keizman, Maya Gottfried, et al. · The Oncologist · 66
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma
2012 · Daniel Keizman, Maya Ish-Shalom, et al. · European Journal of Cancer · 54
PDF
Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma
2016 · Daniel Keizman, Maya Ish-Shalom, et al. · Clinical Genitourinary Cancer · 24
Neoadjuvant Treatment with Paclitaxel and Epirubicin in Invasive??Breast Cancer
2006 · David Sarid, Ilan G Ron, et al. · Clinical Drug Investigation · 15
An animal model for chemotherapy‐associated steatohepatitis and its prevention by the oral administration of fatty acid bile acid conjugate
2009 · Daniel Keizman, Natalie Maimon, et al. · Cancer · 14
PDF
Metastatic Hormone Refractory Prostate Cancer
2012 · Daniel Keizman, Natalie Maimon, et al. · American Journal of Clinical Oncology · 11
Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
2014 · Dana Livne-Segev, Maya Gottfried, et al. · PubMed · 10
Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
2015 · Daniel Keizman, Keren Rouvinov, et al. · Cancer Research and Treatment · 9
PDF
Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?
2013 · Daniel Keizman, Maya Ish-Shalom, et al. · World Journal of Urology · 9
Effect of pectasol-c modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in non-metastatic biochemically relapsed prostate cancer (BRPC) patients (pts): Results of a prospective phase II study.
2018 · Daniel Keizman, Moshe A. Frenkel, et al. · Journal of Clinical Oncology · 5
Pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with ketoconazole (keto): Association with outcome and predictive model.
2012 · Avishay Sella, Maya Ish-Shalom, et al. · Journal of Clinical Oncology · 4
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
2022 · Mor Moskovitz, Elizabeth Dudnik, et al. · The Oncologist · 3
[the Current Approach to Metastatic Renal Cell Carcinoma].
2015 · Daniel Keizman, Natalie Maimon, et al. · PubMed · 3
Patients with metastatic papillary renal cell carcinoma (RCC) who may benefit from sunitinib therapy (tx): Results from an international metastatic RCC database.
2014 · Daniel Kejzman, Maya Gottfried, et al. · Journal of Clinical Oncology · 3
Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease treated with sunitinib.
2012 · Daniel Keizman, Maya Ish-Shalom, et al. · Journal of Clinical Oncology · 3
The association between proton pump inhibitors (PPI) use for gastro-esophageal reflux disease (GERD) and lung cancer (LC): A nested case-control study.
2017 · Hadas Dresler, Daniel Keizman, et al. · Journal of Clinical Oncology · 2
[Metastatic hormone refractory prostate cancer: new treatment horizon].
2012 · Daniel Keizman, Natalie Maimon, et al. · PubMed · 2
Statins (ASIs) may improve the outcome of erlotinib as second line treatment (tx) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC).
2012 · Natalie Maimon, Daniel Keizman, et al. · Journal of Clinical Oncology · 2
Pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with ketoconazole (keto): Association with outcome and predictive model.
2012 · Daniel Keizman, Maya Ish-Shalom, et al. · Journal of Clinical Oncology · 2
Effect of PectaSol-C modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in patients (pts) with nonmetastatic, biochemically relapsed prostate cancer (BRPC): Results of the interim analysis of a prospective phase II study.
2017 · Daniel Keizman, Moshe A. Frenkel, et al. · Journal of Clinical Oncology · 1
Patients with metastatic papillary renal cell carcinoma (RCC) who may benefit from sunitinib therapy (tx): Results from an international metastatic RCC database.
2014 · Jae-Lyun Lee, Maya Gottfried, et al. · Journal of Clinical Oncology · 1
Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease (mRCC) treated with sunitinib (Su).
2012 · Raanan Berger, Daniel Keizman, et al. · Journal of Clinical Oncology · 1
Effect of bisphosphonates (Bis) combined with sunitinib (Su) on the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC).
2012 · Daniel Keizman, Maya Ish-Shalom, et al. · Journal of Clinical Oncology · 1
3rd-line anaplastic lymphoma kinase (ALK) inhibitors (ALKi) in advanced non-small cell lung cancer (aNSCLC): Real-world comparison to non-ALKi therapy.
2020 · Natalie Maimon, Elizabeth Dudnik, et al. · Journal of Clinical Oncology
Works count: 43
Citation count: 335
H-index: 9
I10-index: 8
Year
Topic
Type